Lupin launches generic oral contraceptive tablets in US

NEW DELHI, July 20:  Drug firm Lupin has launched its generic oral contraceptive Norgestimate and ethinyl estradiol tablets in the American market after receiving nod from the US health regulator.
Company’s subsidiary “Lupin Pharmaceuticals Inc has launched its Norgestimate and ethinyl estradiol tablets USP, 0.18 mg / 0.035 mg, 0.215 mg / 0.035 mg and 0.25 mg / 0.035 mg having received an approval from the United States Food and Drug Administration (USFDA)…,” Lupin said.
The USFDA had earlier given approval to market a generic version of Janssen Pharmaceuticals, Inc.’s Ortho Tri-Cyclen tablets in the same strengths, it added.
“Ortho Tri-Cyclen had US sales of USD 177.6 million as per (IMS MAT March 2016),” Lupin said.
The tablets are indicated to prevent pregnancy, it added.
Mumbai-based Lupin manufactures a wide range of branded & generic formulations, biotechnology products and APIs.
Shares of Lupin today closed at Rs 1,713.60 per scrip on BSE, up 1.37 per cent from its previous close. (PTI)